Congenital adrenal hyperplasia

Congenital adrenal hyperplasia refers to a group of inherited disorders, generally transmitted in an autosomal recessive pattern, characterized by a defect in adrenal steroidogenesis that reduces the ability to produce cortisol and, in some forms, aldosterone. This causes a compensatory increase in adrenocorticotropic hormone (ACTH), with consequent adrenal cortical hyperplasia and diversion of steroid precursors toward alternative pathways. The resulting clinical spectrum may include adrenal insufficiency, with a risk of crisis during the first days or weeks of life, fluid and electrolyte disturbances, androgen excess or deficiency and, depending on the enzyme involved, abnormalities of blood pressure and sexual development.

In clinical practice, the importance of congenital adrenal hyperplasia derives from three interconnected factors: the potential neonatal severity of salt-wasting forms, the effect on pubertal development and fertility in hyperandrogenic forms, and the need for long-term management that balances glucocorticoid replacement and control of androgen excess while avoiding iatrogenic complications. Although the disorder is often identified through newborn screening and dedicated pediatric pathways, it persists throughout adulthood and requires continuity of care, structured monitoring and preventive strategies targeting metabolic, cardiovascular, skeletal and reproductive complications.

The epidemiology of congenital adrenal hyperplasia reflects the heterogeneity of its genetic causes and the variable clinical expression of different enzyme defects. The most common form is 21-hydroxylase deficiency, which accounts for the majority of cases and explains why newborn screening focuses primarily on measurement of 17-hydroxyprogesterone. Classic forms, including salt-wasting and simple virilizing phenotypes, have an overall prevalence that varies between populations and screening programs. Nonclassic forms are more common but are frequently underdiagnosed because they present during adolescence or adulthood with subtle endocrine and reproductive manifestations.

The geographical distribution and relative frequency of individual defects may be influenced by founder effects, consanguinity and specific allelic variants that are more prevalent in certain groups. This explains why rare forms such as 11β-hydroxylase deficiency or 17α-hydroxylase deficiency account for a higher proportion of cases in some settings, and why epidemiological interpretation must take into account the local genetic profile and access to molecular diagnosis and endocrine follow-up.

The risk factors are not environmental in the conventional sense, because the disorder is caused by pathogenic variants in genes involved in steroidogenesis or cholesterol transport. However, the probability of detection and the observed clinical severity are influenced by contextual factors. Well-structured newborn screening programs increase early identification of classic forms and reduce the risk of an unrecognized adrenal crisis. In contrast, absent or insufficiently sensitive screening may delay diagnosis until symptoms develop, when dehydration, shock or hyperkalemia-related arrhythmias may already be present.

In nonclassic forms, clinical epidemiology depends strongly on the diagnostic pathways used to evaluate female hyperandrogenism and pubertal disorders. Severe acne, hirsutism, menstrual irregularities and subfertility may prompt endocrine assessment, but the disorder is often confused with more common conditions. This may result in diagnostic delay and prolonged androgen excess, with possible reproductive and metabolic complications. Vulnerability is therefore not solely genetic but also organizational, because it depends on the healthcare system’s ability to recognize a compatible clinical pattern and initiate targeted investigations.

Another epidemiological consideration concerns survival and transition to adult care. The availability of replacement therapy and stress-dose protocols has substantially improved the prognosis of classic forms, but attention has shifted toward long-term outcomes, including excessive glucocorticoid exposure, metabolic risk and quality of life. Congenital adrenal hyperplasia is therefore now regarded as a complex chronic disorder, with a growing adult population requiring integrated models of care between pediatric and adult endocrinology.

Family history is a central determinant of risk. An affected sibling, consanguinity and the identification of carriers within the family increase the probability of recurrence and indicate the need for genetic counseling. In known families, diagnosis can be anticipated and made more precise, reducing the probability of neonatal crises and improving therapeutic appropriateness from the earliest stages of life.

Congenital adrenal hyperplasia results from genetic defects that impair one or more steps in steroid synthesis within the adrenal cortex. Under physiological conditions, the production of cortisol and aldosterone depends on an ordered sequence of enzymatic reactions that convert cholesterol into final hormones through intermediate precursors. Cortisol exerts negative feedback on the hypothalamus and pituitary gland, limiting the secretion of adrenocorticotropic hormone (ACTH). When cortisol production is reduced, this feedback weakens, ACTH secretion increases and the adrenal cortex is persistently stimulated, causing hyperplasia and increasing the flow of steroid precursors. Because these precursors cannot proceed through the blocked pathway, they are diverted toward alternative routes, often leading to increased androgen synthesis.

From an etiological perspective, the main forms include 21-hydroxylase deficiency, 11β-hydroxylase deficiency, 17α-hydroxylase deficiency, rarer defects such as 3β-hydroxysteroid dehydrogenase deficiency and abnormalities of cholesterol transport into the steroidogenic pathway. Clinical variability depends on the combination of residual enzyme activity and physiological demand during different stages of life. A marked reduction in cortisol production during the neonatal period, especially when accompanied by aldosterone deficiency, predisposes to rapid dehydration, hyponatremia, hyperkalemia and metabolic acidosis. Defects with greater residual activity may become apparent later through hyperandrogenism or pubertal abnormalities.

The pathophysiology of androgen excess is central to the most common forms. Increased levels of precursors such as 17-hydroxyprogesterone and androstenedione, with peripheral conversion to testosterone and dihydrotestosterone, may cause virilization of the external genitalia in girls with a female karyotype and precocious puberty or accelerated skeletal maturation in boys. Excess androgens affect not only sexual characteristics but also growth and body composition, with a risk of reduced final height due to advanced bone age and premature closure of the growth plates when endocrine control is inadequate.

When the defect affects mineralocorticoid synthesis, fluid and electrolyte abnormalities become a major component of the disorder. Reduced aldosterone availability impairs sodium reabsorption and the excretion of potassium and hydrogen ions in the distal nephron, promoting hypovolemia and hyperkalemia. In this context, renin activity is a functional marker of salt wasting. Elevated renin indicates inadequate mineralocorticoid action and guides therapeutic adjustment. When present, neonatal crisis is therefore the combined result of cortisol deficiency, salt loss and the inability to sustain the metabolic stress response during the first weeks of life.

Some enzyme defects have a distinctive pathophysiology related to the accumulation of steroids with mineralocorticoid activity or reduced androgen production. In 11β-hydroxylase deficiency, the accumulation of precursors with mineralocorticoid activity may cause hypertension. In 17α-hydroxylase deficiency, reduced androgen production is associated with impaired pubertal development and incomplete secondary sexual characteristics, resulting in a clinical profile that differs from hyperandrogenic forms. These distinctions are essential because they determine diagnostic and therapeutic pathways that are not interchangeable, despite belonging to the same group of disorders.

A final pathophysiological dimension concerns the chronic effects of treatment. Control of androgen excess often requires glucocorticoid doses capable of suppressing ACTH, but prolonged excessive exposure may produce an iatrogenic phenotype characterized by increased risks of overweight, insulin resistance and skeletal fragility. The pathophysiology of the disease and that of its treatment are therefore closely interconnected. The clinical objective is to restore a balance in which glucocorticoid replacement is sufficient to protect against adrenal crisis and control ACTH, without causing long-term metabolic harm.

The clinical manifestations of congenital adrenal hyperplasia depend on the age at presentation, the severity of the enzyme defect and the combination of cortisol deficiency, possible aldosterone deficiency and altered androgen production. Classic forms may present during the first days or weeks of life, when the impaired ability to maintain fluid and electrolyte homeostasis and respond to stress becomes clinically evident. Other forms present during childhood, adolescence or adulthood, with manifestations dominated by hyperandrogenism or abnormalities of pubertal development.

In the neonatal medical history, warning signs include poor weight gain, feeding difficulties, vomiting, lethargy and progressive dehydration. These findings are particularly significant when associated with weight loss and reduced urine output, because they may indicate the onset of adrenal crisis in an undiagnosed newborn. In girls, virilization of the external genitalia may be the first evident clinical sign and prompt immediate diagnostic evaluation. In boys, diagnosis may be more difficult when the external genitalia appear normal, increasing the risk that salt wasting will be the first manifestation.

During childhood, the clinical picture may include initially accelerated growth with advanced bone age, early appearance of pubic hair, acne and adult-type body odor, with possible penile enlargement in boys and clitoromegaly in girls. Androgen excess may create apparent early somatic maturation which, if unrecognized, may ultimately result in reduced final height. At this stage, a history of recurrent vomiting, dehydration during infections or hypoglycemia during stress suggests that the cortisol deficiency is not adequately compensated.

During adolescence and adulthood, nonclassic forms or inadequately controlled disease may present mainly with signs of female hyperandrogenism, including hirsutism, treatment-resistant acne, menstrual irregularities, anovulation and subfertility. In some cases, the symptoms overlap with more common conditions, but early-onset hyperandrogenism, a positive family history and elevated levels of specific steroid precursors support investigation for a congenital disorder. In men, manifestations may be subtler, but reduced fertility, testicular abnormalities caused by testicular adrenal rest tumors and difficulties in optimizing hormonal control during chronic treatment may occur.

On physical examination, in addition to the cutaneous and hair-related signs of hyperandrogenism, hydration status, blood pressure, heart rate and growth parameters must be assessed. Salt-wasting forms may cause hypotension or signs of hypovolemia, whereas some variants may be associated with elevated blood pressure. Pubertal assessment should evaluate the relationship between chronological age and pubertal stage, because discordant advancement may indicate chronic androgen exposure. The distribution of adipose tissue and the presence of striae, skin fragility or rapid weight gain may suggest glucocorticoid overtreatment, which is a crucial consideration in long-term management.

Quality of life and neuropsychological symptoms also require attention. Living with a condition that requires daily treatment and stress management may generate anticipatory anxiety, particularly in patients who have experienced adrenal crises or hospitalization. In adults, clinical assessment should include sexuality, fertility, body image and psychological well-being, because these domains influence treatment adherence and endocrine stability as much as laboratory parameters do.

Congenital adrenal hyperplasia should be suspected when signs of adrenal insufficiency and unexplained androgenization occur in a pattern compatible with a defect of steroidogenesis. During the neonatal period, vomiting, dehydration, weight loss, lethargy and progressive hemodynamic instability should always raise suspicion of cortisol and aldosterone deficiency, particularly when accompanied by hyponatremia and hyperkalemia. Prompt recognition is essential because the condition may progress rapidly and the opportunity to prevent severe complications is limited.

In girls, virilized or ambiguous external genitalia at birth require immediate endocrine and genetic evaluation. An integrated perspective is essential. Genital ambiguity is not an isolated sign but may reflect prenatal androgen excess caused by cortisol deficiency and consequent ACTH hypersecretion. In boys, the absence of an obvious anatomical sign means that clinical suspicion must be based on systemic symptoms, especially when rapid deterioration occurs during the first weeks of life.

During childhood, premature pubarche, accelerated growth with advanced bone age, significant acne and adult-type body odor should prompt evaluation for excessive androgen exposure. The combination of early skeletal maturation and nonphysiological pubertal progression distinguishes a simple early developmental variant from an endocrine disorder that may adversely affect final height. Recurrent episodes of hypoglycemia, particularly during stress or infection, further support the possibility of an underlying glucocorticoid deficiency.

During adolescence and adulthood, suspicion focuses on unexplained female hyperandrogenism characterized by early-onset hirsutism and acne, menstrual irregularities and subfertility. A useful clinical clue is a disproportion between androgenic signs and metabolic abnormalities, or a family history of similar disorders. In adult men with classic disease, infertility or testicular abnormalities detected on palpation or ultrasound may indicate testicular adrenal rest tumors promoted by chronically elevated ACTH, suggesting suboptimal disease control.

Another relevant scenario involves patients with an established diagnosis or those already receiving treatment who develop recurrent instability during infections, surgery or physical stress. Hypotension, persistent nausea, vomiting, profound weakness or confusion may indicate inadequate management of stress doses or poor treatment adherence. In these cases, the issue is not only diagnostic but also related to management, indicating the need to review patient education, the emergency plan and follow-up.

Some rare forms may present with an opposite phenotype, characterized by androgen deficiency and pubertal abnormalities, or with hypertension. Absent or incomplete puberty associated with hypertension and hypokalemia, or discordance between chromosomal sex and pubertal phenotype, should prompt consideration of specific steroidogenesis defects in addition to the more common forms. Early suspicion prevents fragmented diagnostic pathways and permits accurate etiological classification, which is essential for treatment and family counseling.

The diagnosis of congenital adrenal hyperplasia requires a structured pathway integrating clinical findings, biochemical testing and, when indicated, genetic analysis, with different priorities depending on age and severity. In acute neonatal situations, the immediate objective is to rapidly confirm adrenal insufficiency and salt wasting while simultaneously initiating safe management. In nonurgent settings, the aim is to define the responsible enzyme defect and its functional severity, because these factors determine treatment, follow-up and reproductive implications.

First-line investigations include serum electrolytes, blood glucose, blood gas analysis when indicated and markers of mineralocorticoid function. Typical findings in salt-wasting forms include hyponatremia, hyperkalemia and metabolic acidosis, with elevated renin as an indicator of insufficient aldosterone action. Basal cortisol assessment may also be useful, but interpretation must take age, stress and circadian variability into account. For this reason, specific steroid profiles are often more informative in nonemergency settings.

According to Endocrine Society guidelines for the evaluation of the most common forms, diagnosis is based on a stepwise approach beginning with targeted steroid markers and using dynamic testing and genetic analysis when necessary, with attention to analytical interference and circumstances in which newborn screening may produce false-positive results.

Diagnostic assessment of congenital adrenal hyperplasia

• Assessment of safety and severity: electrolytes, blood glucose and markers of salt wasting, including renin, to rapidly identify the risk of hemodynamic instability and the need for urgent replacement therapy.
• Targeted steroid profile: measurement of 17-hydroxyprogesterone as the key test when 21-hydroxylase deficiency is suspected, combined with androgen and precursor measurements according to the clinical phenotype.
• Dynamic testing: stimulation with adrenocorticotropic hormone (ACTH) when baseline values are inconclusive or when nonclassic forms are suspected, with interpretation based on age, sex and laboratory reference ranges.
• Etiological definition: molecular genetic testing or advanced steroid profiling when the presentation is atypical, the enzymatic and functional classification remains uncertain or accurate reproductive counseling is required.

During newborn screening, measurement of 17-hydroxyprogesterone on a dried blood spot is essential for early identification of classic forms, but specificity may be lower in premature or critically ill newborns. Diagnostic confirmation should therefore use serum samples and, when available, more specific steroid measurement methods. The clinical objective is to distinguish an elevation caused by a true enzyme block from transient increases related to neonatal stress or nonspecific conditions.

Identification of the enzyme defect requires pathophysiological interpretation of the steroid profile. A marked increase in 17-hydroxyprogesterone supports 21-hydroxylase deficiency, while other combinations of precursors and metabolites may suggest different defects, particularly when the phenotype includes hypertension or androgen deficiency. In these situations, extended steroid profiling and assessment at specialist endocrine centers reduce the risk of incorrect classification and inappropriate treatment.

In girls with ambiguous or virilized genitalia, diagnosis is not based solely on biochemical testing. Endocrine and genetic assessment must be integrated with pelvic imaging to define internal anatomy and plan a care pathway that considers medical, surgical and psychological factors. The objective is not merely to assign a diagnostic label, but to establish a complete functional diagnosis that guides treatment, follow-up and shared decision-making over time.

The diagnostic process must also include assessment of complications and short-term risk factors. In patients with classic disease, evaluation of vulnerability to adrenal crisis during infection or surgery forms an integral part of the initial assessment because it influences education, emergency planning and follow-up intensity. In adults, evaluation should include blood pressure, metabolic profile and signs of suboptimal control, because the functional diagnosis must be updated over time according to the balance between the disorder and its treatment.

The classification of congenital adrenal hyperplasia links the biochemical defect to the clinical phenotype and helps anticipate risks and therapeutic needs. A first distinction separates forms dominated by cortisol deficiency and the risk of adrenal insufficiency from forms in which mineralocorticoid and androgen abnormalities produce specific manifestations such as salt wasting, hypertension or altered pubertal development. In practice, these domains are often interconnected because the same enzyme defect may cause glucocorticoid deficiency while simultaneously altering androgen and mineralocorticoid production.

In the most common forms caused by 21-hydroxylase deficiency, the traditional clinical classification distinguishes classic from nonclassic forms. Classic disease includes a salt-wasting form, in which mineralocorticoid deficiency is clinically significant, and a simple virilizing form, in which salt loss is absent or less evident but androgen excess is marked. Nonclassic forms retain greater enzyme activity and tend to present later with hyperandrogenism, pubertal abnormalities or reproductive disorders.

A second level of classification is etiological and includes defects other than 21-hydroxylase deficiency. In 11β-hydroxylase deficiency, hyperandrogenism may be accompanied by hypertension due to the accumulation of steroids with mineralocorticoid activity. In 17α-hydroxylase deficiency, the clinical picture may be dominated by reduced androgen production and pubertal abnormalities, with hypertension and hypokalemia in some patients. Rarer defects may produce additional combinations, and the classification must therefore be sufficiently flexible to include noncanonical phenotypes.

Clinical severity depends on the ability to produce cortisol under basal conditions and, above all, during stress. A patient with classic salt-wasting disease is highly vulnerable during the neonatal period and during infections. A patient with nonclassic disease may never experience adrenal crisis but may develop reproductive or metabolic complications over time. Severity therefore does not always correspond to the intensity of androgenic symptoms. A form with moderate hyperandrogenism may still require careful management when glucocorticoid reserve is limited.

Another clinically relevant criterion is the stability of disease control over time. During puberty, pregnancy or transition from pediatric to adult care, hormonal balance may become less stable and require frequent adjustments. The most useful functional classification is therefore dynamic. It describes not only the type of defect and the initial phenotype, but also the tendency to fluctuate between undertreatment and overtreatment, which is a major determinant of long-term complications.

The disorder must ultimately be recognized as a chronic multisystem condition. Clinically useful classification includes metabolic, cardiovascular, skeletal and reproductive dimensions because optimal treatment involves more than normalization of a single marker. It aims to preserve growth, body composition, fertility and safety during stress while reducing the probability of acute events and the burden of complications during adulthood.

Treatment of congenital adrenal hyperplasia is based on a complex therapeutic balance: adequate replacement of deficient cortisol to prevent crisis and ensure an appropriate stress response, modulation of excess adrenocorticotropic hormone (ACTH) to control inappropriate adrenal androgen production, and correction of mineralocorticoid deficiency in salt-wasting forms. The strategy depends on the enzyme defect, functional severity and stage of life, because priorities differ between newborns, growing children, adolescents and adults.

In classic forms, glucocorticoid replacement therapy is essential. During childhood, the objective is to ensure metabolic safety and control hyperandrogenism without impairing growth and skeletal maturation. Doses must be sufficient to reduce ACTH but not so high as to cause chronic excessive exposure, which may result in impaired growth, weight gain and increased metabolic risk. In adults, treatment aims to achieve clinical stability, symptom control and protection against adrenal insufficiency while monitoring blood pressure, body composition and quality of life.

When salt wasting is present, mineralocorticoid therapy with fludrocortisone and adjustment of sodium intake during early life are essential for restoring circulating volume and correcting hyperkalemia and hyponatremia. Clinical response and renin levels guide dose adjustment. Adequate control reduces episodes of dehydration, supports growth and limits excessive activation of the renin-angiotensin system, which may contribute to blood pressure instability over time. In some variants, by contrast, hypertension requires a specific strategy consistent with the accumulation of steroids possessing mineralocorticoid activity.

Management of stress doses is relevant throughout life. During fever, gastroenteritis, trauma or surgery, temporary increases in glucocorticoid therapy are lifesaving. The quality of treatment depends not only on the daily regimen but also on the ability of the patient and family to recognize clinical stress promptly and implement an emergency plan, including alternative routes of administration when oral absorption is impaired. Prevention of adrenal crisis is an integral component of treatment and requires repeated, verified education.

Management of hyperandrogenism and its consequences may require additional interventions. In women with nonclassic disease, who generally have a low risk of adrenal crisis, treatment may focus primarily on controlling hirsutism, acne and ovulatory dysfunction while balancing benefits against the risk of excessive glucocorticoid exposure. In men and women with classic disease, chronic ACTH control reduces the risk of persistent adrenal hyperplasia and complications such as gonadal adrenal rest tissue, which may impair fertility.

Innovative and treatment-optimization approaches include strategies designed to improve the glucocorticoid exposure profile, such as formulations and regimens intended to more closely reproduce physiological circadian rhythms. Pharmacological approaches that reduce ACTH stimulation or modulate steroidogenic pathways are also being investigated, with the aim of reducing the need for supraphysiological glucocorticoid doses to control androgen production. These approaches require careful patient selection and specialist supervision because safety remains the primary clinical criterion, including prevention of adrenal insufficiency and maintenance of stability during stress.

Treatment should also include a multidisciplinary approach in patients with differences of sex development and during transitional stages. Management cannot be reduced to a laboratory value but must integrate endocrinology, psychology, gynecology or andrology, genetics and, when indicated, specialist surgery. Decisions should be reviewed over time according to growth, puberty, identity, reproductive function and informed preferences.

Follow-up of congenital adrenal hyperplasia is a continuous process aimed at preventing adrenal crises, maintaining stable hormonal control and reducing complications caused by both the disorder and its treatment. The frequency of follow-up depends on age and clinical stage. Assessments are more frequent in newborns and infants because of their vulnerability to fluid and electrolyte disturbances and rapidly changing treatment requirements. In adults, monitoring focuses on stability, metabolic prevention and reproductive health, with closer reassessment during transitions or periods of instability.

Laboratory monitoring includes safety parameters and markers of steroidogenesis control. Electrolytes and renin are essential in salt-wasting forms to evaluate the adequacy of mineralocorticoid action. With regard to androgen control, levels of precursors such as 17-hydroxyprogesterone and adrenal androgens help identify undertreatment associated with excessive ACTH or overtreatment associated with excessive glucocorticoid exposure. Interpretation must consider the timing of medication administration and physiological rhythms, because isolated values do not always reflect overall hormonal exposure.

In children and adolescents, follow-up must include growth, weight, blood pressure and assessment of skeletal maturation. Measurement of bone age is a key clinical indicator because it reflects cumulative androgen exposure and guides therapeutic changes before the effect on final height becomes irreversible. Pubertal assessment should verify progression and its consistency with age, because early or accelerated puberty may indicate suboptimal control. Signs of excessive glucocorticoid exposure, including reduced growth velocity, rapid weight gain and skin fragility, must also be monitored.

In adults, surveillance expands to include metabolic and cardiovascular risk. Chronic therapy and possible excessive glucocorticoid exposure may promote increased fat mass, reduced lean mass and worsening insulin resistance. Blood pressure must be carefully monitored because it may be influenced by mineralocorticoid dosage, individual sensitivity and enzyme variants associated with steroids that have mineralocorticoid activity. Follow-up therefore includes assessment of weight, waist circumference, glucose and lipid profiles, and skeletal health, because effective long-term management aims to reduce cardiovascular events and fragility.

Reproductive health requires dedicated attention. In women, control of hyperandrogenism is essential for ovulatory regularity and fertility, and management must be adapted to pregnancy planning and hormonal changes. In men with classic disease, surveillance for testicular adrenal rest tumors and gonadal function is important to prevent reduced fertility. In both sexes, quality of life, sexuality and psychological well-being should be actively assessed because they influence treatment adherence and the ability to manage stress dosing correctly.

Effective follow-up also requires repeated education and verification of the patient’s competence in emergency management. The stress-dose plan, early recognition of signs of adrenal crisis and availability of emergency therapy must be updated and reinforced over time. Clinical stability means more than the absence of symptoms. It also requires the ability to prevent acute events during the inevitable episodes of biological stress that occur throughout life.

The prognosis of congenital adrenal hyperplasia is generally favorable when diagnosis is early, treatment is adequate and the patient has a well-established stress management plan. In classic forms, prevention of adrenal crisis and stabilization of fluid and electrolyte balance during the first months of life are the main determinants of short-term outcomes. Long-term prognosis depends on the quality of therapeutic balance. Effective control of ACTH limits androgen excess and its effects on growth and reproductive function, while avoiding excessive glucocorticoid exposure reduces the risk of iatrogenic complications.

The most critical complications are associated with adrenal insufficiency. Vomiting, diarrhea, high fever or trauma may precipitate a crisis when stress doses are not administered promptly or oral absorption is impaired. Adrenal crisis may present with hypotension, electrolyte abnormalities and hypoglycemia and remains a lifelong risk. Patient education and access to emergency treatment are therefore as important to prognosis as the daily replacement dose.

A second group of complications results from chronic hyperandrogenism or inadequate control. During childhood, advanced bone age and precocious puberty may reduce final height. In adults, persistent hyperandrogenism may cause menstrual disorders, anovulation and subfertility in women and contribute to gonadal dysfunction and reduced fertility in men. Prolonged ACTH elevation may promote the growth of ectopic adrenal tissue, including gonadal adrenal rest tissue, with clinical consequences requiring dedicated surveillance.

Metabolic and cardiovascular complications account for a substantial proportion of the long-term burden. Excessive glucocorticoid therapy may promote weight gain, impaired glucose metabolism and reduced lean mass. Blood pressure may also be influenced by mineralocorticoid dosage, individual sensitivity and enzyme variants associated with steroids that possess mineralocorticoid activity. For this reason, prognosis in adults is assessed not only according to the absence of adrenal crises but also according to cardiovascular prevention and preservation of favorable body composition.

The skeletal and muscular systems represent another area of potential complications. Chronic glucocorticoid exposure may reduce bone mineral density and increase fragility, while endocrine instability may affect muscle mass and function. Some patients develop benign adrenal lesions such as myelolipomas, which are more frequent in the presence of chronic stimulation and may become clinically relevant because of their size or local complications. Surveillance and prevention depend on adequate ACTH control and appropriate treatment, confirming that long-term management is the main determinant of prognosis.

Overall, congenital adrenal hyperplasia is a complex chronic disorder requiring early diagnosis, individualized treatment, structured education regarding stress management and multidimensional follow-up. Prognosis is not determined by a single parameter but by the ability to maintain a long-term balance between protection from adrenal crisis and reduction of the effects of hyperandrogenism while avoiding glucocorticoid-related iatrogenic complications, which may eventually become as important a cause of morbidity as the disorder itself.